Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study.
COVID-19
Coronavirus disease
Immunoglobulin M
Immunoglobulins
SARS-CoV-2
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
07 07 2022
07 07 2022
Historique:
received:
22
04
2022
accepted:
13
06
2022
entrez:
7
7
2022
pubmed:
8
7
2022
medline:
12
7
2022
Statut:
epublish
Résumé
A profound inflammation-mediated lung injury with long-term acute respiratory distress and high mortality is one of the major complications of critical COVID-19. Immunoglobulin M (IgM)-enriched immunoglobulins seem especially capable of mitigating the inflicted inflammatory harm. However, the efficacy of intravenous IgM-enriched preparations in critically ill patients with COVID-19 is largely unclear. In this retrospective multicentric cohort study, 316 patients with laboratory-confirmed critical COVID-19 were treated in ten German and Austrian ICUs between May 2020 and April 2021. The primary outcome was 30-day mortality. Analysis was performed by Cox regression models. Covariate adjustment was performed by propensity score weighting using machine learning-based SuperLearner to overcome the selection bias due to missing randomization. In addition, a subgroup analysis focusing on different treatment regimens and patient characteristics was performed. Of the 316 ICU patients, 146 received IgM-enriched immunoglobulins and 170 cases did not, which served as controls. There was no survival difference between the two groups in terms of mortality at 30 days in the overall cohort (HR Although we cannot prove a statistically reliable effect of intravenous IgM-enriched immunoglobulins, the confidence intervals may suggest a clinically relevant effect in certain subgroups. Here, an early administration (i.e. in critically ill but not yet mechanically ventilated COVID-19 patients) and a dose of ≥ 15 g for at least 3 days may confer beneficial effects without concerning safety issues. However, these findings need to be validated in upcoming randomized clinical trials. Trial registration DRKS00025794 , German Clinical Trials Register, https://www.drks.de . Registered 6 July 2021.
Sections du résumé
BACKGROUND
A profound inflammation-mediated lung injury with long-term acute respiratory distress and high mortality is one of the major complications of critical COVID-19. Immunoglobulin M (IgM)-enriched immunoglobulins seem especially capable of mitigating the inflicted inflammatory harm. However, the efficacy of intravenous IgM-enriched preparations in critically ill patients with COVID-19 is largely unclear.
METHODS
In this retrospective multicentric cohort study, 316 patients with laboratory-confirmed critical COVID-19 were treated in ten German and Austrian ICUs between May 2020 and April 2021. The primary outcome was 30-day mortality. Analysis was performed by Cox regression models. Covariate adjustment was performed by propensity score weighting using machine learning-based SuperLearner to overcome the selection bias due to missing randomization. In addition, a subgroup analysis focusing on different treatment regimens and patient characteristics was performed.
RESULTS
Of the 316 ICU patients, 146 received IgM-enriched immunoglobulins and 170 cases did not, which served as controls. There was no survival difference between the two groups in terms of mortality at 30 days in the overall cohort (HR
CONCLUSIONS
Although we cannot prove a statistically reliable effect of intravenous IgM-enriched immunoglobulins, the confidence intervals may suggest a clinically relevant effect in certain subgroups. Here, an early administration (i.e. in critically ill but not yet mechanically ventilated COVID-19 patients) and a dose of ≥ 15 g for at least 3 days may confer beneficial effects without concerning safety issues. However, these findings need to be validated in upcoming randomized clinical trials. Trial registration DRKS00025794 , German Clinical Trials Register, https://www.drks.de . Registered 6 July 2021.
Identifiants
pubmed: 35799196
doi: 10.1186/s13054-022-04059-0
pii: 10.1186/s13054-022-04059-0
pmc: PMC9260992
doi:
Substances chimiques
Immunoglobulin M
0
Immunoglobulins, Intravenous
0
Banques de données
DRKS
['DRKS00025794']
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
204Informations de copyright
© 2022. The Author(s).
Références
Int Immunopharmacol. 2021 Jan;90:107205
pubmed: 33214093
Front Immunol. 2021 Feb 19;12:627844
pubmed: 33679771
Nat Rev Immunol. 2013 Mar;13(3):176-89
pubmed: 23411799
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Crit Care. 2019 Nov 27;23(1):374
pubmed: 31775846
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
Life Sci. 2021 Mar 15;269:119010
pubmed: 33454368
BMC Infect Dis. 2020 Oct 21;20(1):786
pubmed: 33087047
Cell Mol Immunol. 2018 Jun;15(6):563-574
pubmed: 29375122
Crit Care Med. 2020 Jun;48(6):e440-e469
pubmed: 32224769
Semin Immunopathol. 2018 Nov;40(6):567-575
pubmed: 30310974
Immunology. 1998 Jun;94(2):279-83
pubmed: 9741353
Crit Care. 2021 Aug 17;25(1):295
pubmed: 34404458
Blood. 2021 Mar 11;137(10):1406-1415
pubmed: 33512411
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Clin Rev Allergy Immunol. 2005 Dec;29(3):173-84
pubmed: 16391392
Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102
pubmed: 32258207
Front Immunol. 2021 May 10;12:682871
pubmed: 34040616
J Infect. 2020 Aug;81(2):318-356
pubmed: 32283154
Cytokine. 2021 Dec;148:155628
pubmed: 34411989
Clin Exp Immunol. 1997 Jan;107(1):50-6
pubmed: 9010256
Stat Appl Genet Mol Biol. 2007;6:Article25
pubmed: 17910531
Antibodies (Basel). 2020 Oct 13;9(4):
pubmed: 33066119
Clin Ther. 2019 Sep;41(9):1823-1838.e4
pubmed: 31470986
Int Immunopharmacol. 2021 Jul;96:107732
pubmed: 34162133
Ann Intensive Care. 2020 Oct 07;10(1):132
pubmed: 33026597
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Crit Care Resusc. 2013 Dec;15(4):287-93
pubmed: 24289510
Am J Pathol. 2021 Jan;191(1):4-17
pubmed: 32919977
Clin Transl Immunology. 2020 Oct 16;9(10):e1198
pubmed: 33088506
J Clin Invest. 2021 Oct 15;131(20):
pubmed: 34464357
JCI Insight. 2020 Sep 3;5(17):
pubmed: 32687484
Lancet Respir Med. 2022 Feb;10(2):158-166
pubmed: 34774185
BMC Pulm Med. 2021 Nov 8;21(1):354
pubmed: 34743710
Clin Transl Immunology. 2020 Oct 14;9(10):e1192
pubmed: 33082954